All In Biotech

Drug Trial Radar · NCT04415060

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Jun 15, 2020

Primary completion

Mar 17, 2025

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Sunnybrook Health Sciences CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients suffering lung failure, possibly from COVID-19 or hypoxic lung failure, will need life-saving support from a breathing machine. Any patient needing this support requires drugs to keep them sleepy, or "sedated" to be comfortable on this machine. Sedation is made possible by using drugs given through a vein. Unfortunately, these drugs are in short supply worldwide due to the high number of COVID-19 patients needing these machines. Another way to provide sleep is by using gases that are breathed in. These are used every day in operating rooms to perform surgery. These gases, also called "inhaled agents" can also be used in intensive care units and may have several important benefits for patients and the hospital. Research shows they may reduce swelling in the lung and increase oxygen levels, which allows patients to recover faster and reduce the time spent on a breathing machine. In turn, this allows the breathing machine to be used again for the next sick patient. These drugs may also increase the number of patients who live through their illness. Inhaled agents are widely available and their use could dramatically lesson the pressure on limited drug supplies. This research is a study being carried out in a number of hospitals that will compare how well patients recover from these illnesses depending on which type of sedation drug they receive. The plan is to evaluate the number who survive, their time spent on a breathing machine and time in the hospital. This study may show immediate benefits and may provide a cost effective and practical solution to the current challenges caring for patients and the hospital space, equipment and drugs to the greatest benefit. Furthermore, the study will be investigating inflammatory profile and neuro-cognitive profiles in ventilated patients. Finally, this trial will be a team of experts in sedation drugs who care for patients with proven or suspected COVID-19 who need lifesaving treatments.

Conditions

  • Covid19
  • Hypoxic Respiratory Failure

Interventions

  • Isoflurane Inhalant ProductDrug

    Isoflurane will be administered using an inhalation device

  • Sevoflurane inhalant productDrug

    Sevoflurane will be administered using an inhalation device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospital MortalityTime frame: 365 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Grey Nuns Community Hospital

    Edmonton, Alberta, Canada

  • London Health Sciences Centre - University Hospital

    London, Ontario, Canada

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • University Health Network - Toronto General Hospital

    Toronto, Ontario, Canada

  • University Health Network - Toronto Western Hopsital

    Toronto, Ontario, Canada

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada

  • McGill University Health Centre - Royal Victoria Hospital

    Montreal, Quebec, Canada

  • Hôpital Sacré-Coeur de Montréal

    Montreal, Quebec, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)

    Québec, Quebec, Canada

  • Universite de Sherbrooke

    Sherbrooke, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.